Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer
- 1 December 1995
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 13 (4) , 343-345
- https://doi.org/10.1007/bf00873142
Abstract
The objective of this multicenter phase II study was to evaluate the activity of docetaxel in previously untreated small cell lung cancer. Fourteen patients were treated at a dose of 75 mg/m2 intravenously every three weeks. Of the 12 patients evaluable for response, one had a partial response for a duration of 12 weeks for a response rate of 8.3%. Toxicity was mild. We conclude that docetaxel has, at the dose given in this study, little activity in previously untreated small cell lung cancer.Keywords
This publication has 2 references indexed in Scilit:
- Activity of docetaxel (Taxotere) in small cell lung cancerEuropean Journal Of Cancer, 1994
- Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kindAnnals of Oncology, 1994